// App-Quantinova.ai

2734 : Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Researchers

Presenter

  • Ohad Benjamini

Principal Investigators

  • Hagop M. Kantarjian

  • Susan -Brien

  • Rajyalakshmi Luthra

  • Jorge Cortes

  • Deborah A. Thomas

  • Farhad Ravandi

  • Preetesh Jain

  • Sherry Pierce

  • Gautam Borthakur

  • Tapan M. Kadia

  • Elias Jabbour

  • Zeev Estrov

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Philadelphia chromosome–positive (Ph+) ALL

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Omacetaxine mepesuccinate

  • Vincristine

  • Adriamycin injection

  • Bosutinib

  • Nilotinib

  • Ponatinib

  • dasatinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved